Back to results
US 2021/0277057 A1Published application
Advantageous mu-opiate receptor peptide compounds
AssigneeCytogel Pharma, LLC
InventorTheodore E. MAIONE
Life of this patent
Estimating the term…
Abstract
The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.
Claims7
A safe and effective method for treating a condition in a human that is modulated by μ-opiate receptor activity, wherein said method comprises administering, to a human patient in need of such treatment, a peptide compound wherein the compound is the acetate salt of SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.